Full video transcriptClick to expand
Auto-generated transcript of @zari.bilall's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00As much as I love Manjauro, I think it's where my life will go.
- 0:03So I lost 25.5 King lows in the space of 4-5 months.
- 0:08And I looked trash-broken and tired from the pain the whole night.
- 0:12Manjau has given me gas varieties and I'm gonna be honest with you that is a killing.
- 0:17I don't know what it is, but it's literally a killer.
- 0:20It's been two months, so in an hour of hospitals, getting dripped and everything.
- 0:24Because the pain radiates here.
- 0:27Right, when it comes, it is so bad.
- 0:30If I eat anything, if I don't eat anything, whatever it is, my day to day life.
- 0:35It happens in the night. It has no time. It just basically happens, right?
- 0:40I've had that all finger done, blood tests done and every blood test, it just says, you know, it's okay.
- 0:48I had it live for my liver test. It came out but as if the liver's a bit rise down something.
- 0:54I don't know if it's because of Manjauro.
- 0:56But I've got gastriitis because of Manjauro and the pain.
- 0:59When it starts here, it is so bad, so bad and so unbearable.
- 1:04It's just shot, shooting, and then I've never had it in my life.
- 1:07I think it's a Manjauro, I have it.
- 1:09But I can't blame Manjauro because it helped me lose the weight.
- 1:12But it has given me sad pics for a long term, I don't know.
Does Mounjaro cause gastritis? What the evidence actually shows
Quick answer
The creator describes new-onset severe epigastric and radiating abdominal pain beginning after starting tirzepatide (Mounjaro), with multiple hospital admissions for IV fluid support and mildly abnormal liver enzymes. Tirzepatide's dual GLP-1 and GIP receptor agonism significantly delays gastric emptying, creating a plausible mechanism for gastric mucosal irritation and gastritis-like symptoms. Formal gastritis diagnosis requires endoscopic confirmation, which does not appear to have occurred based on her account, making causal attribution plausible but not yet clinically confirmed.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does Mounjaro cause gastritis? What the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Does Mounjaro cause gastritis? What the evidence actually shows" from Zarii | SAHM OF 5🌷. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes new-onset severe epigastric and radiating abdominal pain beginning after starting tirzepatide (Mounjaro), with multiple hospital admissions for IV fluid support and mildly abnormal liver enzymes.
The reason this review is not generic is the source wording and the canonical claim label "glp1 as much as i love mounjaro i can hands down say it has ruine." In this clip, the useful excerpt is: "As much as I love Manjauro, I think it's where my life will go." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator describes new-onset severe epigastric and radiating abdominal pain beginning after starting tirzepatide (Mounjaro), with multiple hospital admissions for IV fluid support and mildly abnormal liver enzymes.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes new-onset severe epigastric and radiating abdominal pain beginning after starting tirzepatide (Mounjaro), with multiple hospital admissions for IV fluid support and mildly abnormal liver enzymes. Tirzepatide's dual GLP-1 and GIP receptor agonism significantly delays gastric emptying, creating a plausible mechanism for gastric mucosal irritation and gastritis-like symptoms. Formal gastritis diagnosis requires endoscopic confirmation, which does not appear to have occurred based on her account, making causal attribution plausible but not yet clinically confirmed.
- Tirzepatide delays gastric emptying via dual GLP-1 and GIP receptor agonism, a documented mechanism that can increase gastric acid contact time and plausibly cause gastritis-like symptoms.
- A 2023 JAMA study (Sodhi et al.) found GLP-1 receptor agonists were associated with significantly higher rates of gastroparesis, pancreatitis, and bowel obstruction vs. non-GLP-1 controls.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide delays gastric emptying via dual GLP-1 and GIP receptor agonism, a documented mechanism that can increase gastric acid contact time and plausibly cause gastritis-like symptoms.
- A 2023 JAMA study (Sodhi et al.) found GLP-1 receptor agonists were associated with significantly higher rates of gastroparesis, pancreatitis, and bowel obstruction vs. non-GLP-1 controls.
- Pancreatitis is listed as a warning in Mounjaro's official prescribing label. Persistent or severe abdominal pain in any patient on tirzepatide should be evaluated promptly and not assumed to be routine GI side effects.
- Normal blood tests do not rule out gastritis or gastroparesis. Both conditions require endoscopy or gastric emptying studies for formal diagnosis.
- Rapid weight loss of the magnitude described, around 25 kg in 4-5 months, is itself a known cause of transient liver enzyme elevation due to fat mobilization, independent of direct drug toxicity (Chalasani et al., Hepatology 2018).
- GI side effects are the most common reason patients discontinue GLP-1 and GIP receptor agonists in clinical trials. Dose escalation pace is a modifiable factor that can reduce severity.
- Anyone developing new upper abdominal pain after starting a GLP-1 or GIP receptor agonist should document the timeline relative to dose increases and report it to their prescriber rather than self-managing.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @zari.bilall actually say?
She said Mounjaro (tirzepatide) gave her gastritis, describing pain so severe it sent her to hospital multiple times for IV fluids. In her words, the pain "radiates" and is "so bad, so bad and so unbearable." She also mentioned abnormal liver results and lost 25.5 kilograms in four to five months. She's careful not to fully blame the drug, saying "I can't blame Mounjaro because it helped me lose the weight," but she draws a direct causal line between starting tirzepatide and developing gastritis for the first time in her life. She's not claiming a cure or pushing a product. She's describing a personal medical experience with a prescription drug, which is a different kind of content, and it deserves a serious look, not dismissal.
Does the science back this up?
Yes, more than most people realize. GLP-1 and GIP receptor agonists slow gastric emptying, which increases the time stomach acid stays in contact with the gastric lining. That's a plausible biological mechanism for gastritis. A 2023 JAMA study (Sodhi et al., JAMA 2023) found GLP-1 receptor agonists were associated with significantly higher rates of gastrointestinal adverse events, including gastroparesis, compared to controls. Tirzepatide, which acts on both GLP-1 and GIP receptors, slows motility more than semaglutide in some comparisons. The prescribing information for Mounjaro lists nausea, vomiting, and abdominal pain as very common side effects, but gastritis specifically is underreported in trials, likely because it requires endoscopy to formally diagnose, which isn't routine in clinical trials.
- Sodhi M et al., JAMA 2023: GLP-1 RAs associated with increased gastroparesis, pancreatitis, and bowel obstruction risk vs. bupropion-naltrexone controls.
- Delayed gastric emptying is a documented pharmacological effect of tirzepatide (Eli Lilly prescribing information, 2022).
What did they get wrong (or right)?
She got the main point right: tirzepatide can plausibly cause or worsen gastritis, and her symptom pattern, nocturnal pain, pain regardless of eating, radiating discomfort, is consistent with gastric mucosal irritation. She deserves credit for that. What she got less right is the certainty of causation. She says "I've got gastritis because of Mounjaro" as a settled fact, but her blood tests were largely normal and she doesn't mention an endoscopy, which is the actual diagnostic standard for gastritis. The liver result she mentions, "the liver's a bit rise down something," is vague and could reflect rapid weight loss itself rather than drug toxicity. Rapid fat mobilization during fast weight loss is a known cause of transient liver enzyme elevation. That's not wrong of her to flag, but attributing it to the drug specifically isn't supported by what she describes.
What should you actually know?
If you're on a GLP-1 or GIP receptor agonist and developing new upper abdominal pain, don't self-diagnose and don't just push through it. Gastritis, gastroparesis, and pancreatitis can all present with similar symptoms, and pancreatitis in particular is a serious adverse event flagged in tirzepatide's label. The Sodhi et al. 2023 data showed a roughly ninefold increased risk of pancreatitis with GLP-1 RAs compared to some controls, which is not a small signal. A formal diagnosis requires imaging or endoscopy, not just blood tests. If your bloods come back normal but you're still in severe pain, push for further investigation. Normal labs do not rule out gastritis or early gastroparesis. Bring the timeline to your prescriber: when symptoms started relative to your dose increases matters for working out what's going on.
- Pancreatitis is listed as a warning in Mounjaro's prescribing label. Persistent abdominal pain should be evaluated promptly.
- Transient liver enzyme elevation is common with rapid weight loss independent of drug effects (Chalasani et al., Hepatology 2018).
- A formal gastritis diagnosis requires endoscopy. Blood tests and symptom history alone are insufficient.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Zarii | SAHM OF 5🌷 · TikTok creator
506.9K views on this video
As much as I love Mounjaro, I can hands down say it has ruined a part of me. I’ve never had gastritis, in my life but now I do. #sideffects #sideeffects #fyp #mounjaro #mounjarosideeffect #gastritis #viraltok
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide delays gastric emptying via dual glp-1?
Tirzepatide delays gastric emptying via dual GLP-1 and GIP receptor agonism, a documented mechanism that can increase gastric acid contact time and plausibly cause gastritis-like symptoms.
What does the video say about a 2023 jama study (sodhi et al.) found glp-1 receptor?
A 2023 JAMA study (Sodhi et al.) found GLP-1 receptor agonists were associated with significantly higher rates of gastroparesis, pancreatitis, and bowel obstruction vs. non-GLP-1 controls.
What does the video say about pancreatitis?
Pancreatitis is listed as a warning in Mounjaro's official prescribing label. Persistent or severe abdominal pain in any patient on tirzepatide should be evaluated promptly and not assumed to be routine GI side effects.
What does the video say about normal blood tests do not rule out gastritis?
Normal blood tests do not rule out gastritis or gastroparesis. Both conditions require endoscopy or gastric emptying studies for formal diagnosis.
What does the video say about rapid weight loss of the magnitude described, around 25 kg?
Rapid weight loss of the magnitude described, around 25 kg in 4-5 months, is itself a known cause of transient liver enzyme elevation due to fat mobilization, independent of direct drug toxicity (Chalasani et al., Hepatology 2018).
What does the video say about gi side effects?
GI side effects are the most common reason patients discontinue GLP-1 and GIP receptor agonists in clinical trials. Dose escalation pace is a modifiable factor that can reduce severity.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Zarii | SAHM OF 5🌷, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.